NYSE:ABBV coming into some major support here:
A descending TL from ATH that was resistance before
2 year volume shelf starting at 155
200SMA on daily
waiting to see how it reacts
* long above 160 & hold on daily
* not willing to short it
key points:
* Humira sales declining further as more competition mounts
* Other drug sales increase compensating...
AbbVie Inc. ( NYSE:ABBV ) struggles with declining sales volumes of its blockbuster arthritis drug, Humira. Despite a positive outlook for its newer immunology treatments, Skyrizi and Rinvoq, concerns over the impact of biosimilar competition and shifting patient preferences have cast a shadow over the pharmaceutical giant's performance, leading to a dip in its...
ABBV NEEDS to start holding support now if it wants to continue higher. it is buyable as of now, BUT, if we start breaking the swing high (labeled with a red line) this will be in trouble and could see a drop down to sub $120.
Pharmaceutical giant AbbVie Inc. is considering enhancing its neurobiological portfolio as it finalises the acquisition of neurobiotech firm Cerevel Therapeutics. Initially announced in December 2023 for 8.7 billion USD, the acquisition was primarily focused on Cerevel's experimental schizophrenia drug, Emraclidine. This drug represents a new class of...
NYSE:ABBV is a great company. It's part of my long-term portfolio and is one that I've been able to manage well with technical analysis.
I am not adding unless I see price fall to 155 or until we get to August/September where it hits its seasonal low. This drawdown has risk of continuation for a number of reasons:
Momentum was falling as price was rising....
Entry Price (173.97) : Chosen based on Fibonacci retracement levels, suggesting a potential point to buy or enter the stock, expecting the price to increase from this level.
Take Profit (179.97) : Set near a Fibonacci extension or resistance level, indicating a target price to sell and secure profits before the stock might pull back.
Stop Loss (171.97) :...
ABBV - 135 level would’ve been ideal entry for long but it’s not too late to join the party.
It's just cleared 155 level.
Next, gap fill above upto 165.
After that, Target 1 : 175
Hey everyone!
Today we're taking a look at Abbvie, NYSE:ABBV a popular U.S. pharmaceutical stock.
In the chart above, we've combined a momentum view with a support & resistance framework to point out high points and low points of the recent range ABBV has been trading in.
In combination with the momentum indicator, it appears as though the chances of a break...
If you haven`t bought the dip on ABBV:
Then analyzing the options chain and the chart patterns of ABBV AbbVie prior to the earnings report this week,
I would consider purchasing the 160usd strike price Calls with
an expiration date of 2024-3-15,
for a premium of approximately $7.55.
If these options prove to be profitable prior to the earnings release, I would...
Ciao,
pretty distinguishable balance between supply and demand for Abbvie. Looking to trade in the range, stop losses below the potential stop hunt -levels.
Good luck with the shopping!
Strong bull flag continuation pattern forming here on ABBV. There's big gap fill potential above supply zone so expect resistance break to get us to 159 quickly. Gains after that should be slower but expecting an $8-9 move above current supply zone based on the height of the flag pole. Please see chart for more details.
Hi Traders!
Let's take a look at ABBV on the daily timeframe. The price has been forming the descending channel pattern for the last months. The price is at the downsloping resistance line right now. We expect the price to fall from here down to the downsloping support line and bounce up from the strong horizontal support. We would enter long when the price reach...
About Abbvie:
Abbvie Inc. (NYSE: ABBV) stands as a prominent player in the pharmaceutical industry, known for its diverse product portfolio and strategic market positioning. This analysis delves into AbbVie's financial health, growth projections, and its competitive landscape.
Financial Highlights:
With a robust revenue of $58.054 billion in 2022 and a...
ABBV is on a bearish 1D technical outlook (RSI = 39.987, MACD = -1.990, ADX = 42.078) but is quite possibly forming a short term bottom as the 1D RSI rebounded from an oversold level (under 30.00), while the MACD is close to forming a Bullish Cross. Every time those two conditions were fulfilled simultaneously inside the 1 year Channel Down, the price was a buy....
If you haven`t bought the dip on ABBV here:
Then analyzing the options chain and the chart patterns of ABBV AbbVie prior to the earnings report this week,
I would consider purchasing the 147usd strike price Calls with
an expiration date of 2023-11-17,
for a premium of approximately $3.30.
If these options prove to be profitable prior to the earnings release, I...
